secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-12-04T23:59:59+00:00
Accession:  0000950170-24-133076
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint dosed first patient in second Phase 3 wet AMD trial (LUCIA); topline data expected 2026
--------------------------------------------------------------------------------

- First patient dosed in LUCIA, the second global Phase 3 trial of DURAVYU (vorolanib Durasert E) for wet AMD.
- LUCIA follows LUGANO trial; both are randomized, double-masked, non-inferiority vs aflibercept with ~400 patients each.
- Primary endpoint: average change in BCVA at weeks 52 and 56; re-dosing every six months.
- Topline data from Phase 3 pivotal program anticipated in 2026; over 240 global sites committed.
- CEO cites robust interest and strong balance sheet; LUGANO enrollment exceeded expectations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024133076/0000950170-24-133076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024133076/eypt-20241204.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-133076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer